Effect of Qianggan capsules on insulin resistance index and liver fibrosis score in patients with nonalcoholic fatty liver disease

Ou Qiang; Xu YanHua; Qu LiJuan; Huang Ling

doi:10.3969/j.issn.1001-5256.2016.10.027

Issue 10

Oct. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(10): 1951-1954

PDF( 1532 KB)

Effect of Qianggan capsules on insulin resistance index and liver fibrosis score in patients with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2016.10.027

Department of Infectious Diseases, The Eighth People′s Hospital of Shanghai

Published Date: 2016-10-20

Abstract

Abstract

Objective To investigate the effect of Qianggan capsules on liver fibrosis score and insulin resistance index in patients with nonalcoholic fatty liver disease( NAFLD). Methods A total of 85 NAFLD patients who were treated in the Eighth People's Hospital of Shanghai from August 2014 to July 2015 were enrolled and randomly divided into treatment group( 45 patients) and control group( 40 patients).The patients in the treatment group were given Qianggan capsules,and those in the control group were given polyene phosphatidylcholine capsules. The course of treatment was 24 weeks for both groups. The changes in serum aminotransferases [aspartate aminotransferase( AST)and alanine aminotransferase( ALT) ],homeostasis model assessment of insulin resistance( HOMA-IR),and NAFLD fibrosis score( NAFLDFS) after treatment were observed in both groups. The t-test was used for comparison of continuous data between groups,before-after comparison within each group was made by paired t-test; and the chi-square test was used for comparison of categorical data between groups. Results Both groups showed significant improvements in ALT and AST levels after treatment( all P < 0. 01). After treatment the treatment group showed significant reductions in HOMA-IR and NAFLDFS( 3. 58 ± 0. 85 vs 2. 48 ± 0. 78,t = 6. 40,P < 0. 01;-1. 78 ±1. 24 vs-2. 35 ± 0. 98,t = 2. 40,P < 0. 01) and the treatment group had significantly lower HOMA-IR and NAFLDFS than the control group( 12. 48 ± 0. 78 vs 3. 09 ± 0. 89,t = 3. 36,P < 0. 01;-2. 35 ± 0. 98 vs-1. 48 ± 1. 08,t = 3. 80,P < 0. 01). No serious adverse events were observed during the course of treatment. Conclusion Qianggan capsules not only reduce the levels of serum aminotransferases,but also improve insulin resistance and reduce fibrosis degree in NAFLD patients.
- fatty liver,
- Qianggan capusule,
- insulin resistance,
- nonalcoholic fatty liver disease fibrosis score

FullText(HTML)

References(18)

References

[1]RAU M,WEISS J,GEIER A.Non-alcoholic fatty liver disease(NAFLD)[J].Dtsch Med Wochenschr,2015,140(14):1051-1055.

[2]JI XL,GE YD,AN MM,et al.Correlation analysis between nonalcoholic fatty liver disease and metabolic syndrome[J].Chin J Clin Pharmacol Ther,2014,19(6):666-670.(in Chinese)季学磊,葛艺东,安民民,等.非酒精性脂肪肝与代谢综合征的临床相关性分析[J].中国临床药理学与治疗学,2014,19(6):666-670.

[3]YAN J,XIE W,OU WN,et al.Epidemiological survey and risk factor analysis of fatty liver disease of adult residents,Beijing,China[J].J Gastroenterol Hepatol,2013,28(10):1654-1659.

[4]ANGULO P.Long-term mortality in nonalcoholic fatty liver disease:is liver histology of any prognostic significance?[J].Hepatology,2010,51(5):373-375.

[5] Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association.Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases(revised in January 2010)[J].Chin J Intern Med,2010,49(3):275-278.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年1月修订)[J].中华内科杂志,2010,49(3):275-278.

[6]FRIEDMAN SL.Liver fibrosis in 2012:Convergent pathways that cause hepatic fibrosis in NASH[J].Nat Rev Gastroenterol Hepatol,2013,10(2):71-72.

[7]VERNON G,BARANOVA A,YOUNOSSI ZM.Systematic review:the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther,2011,34(3):274-285.

[8]SANAL MG.Biomarkers in nonalcoholic fatty liver disease:theemperor has no clothes?[J].World J Gastroenterol,2015,21(11):3223-3231.

[9]SHEN F,ZHENG RD,MI YQ,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients[J].World J Gastroenterol,2014,20(16):4702-4711.

[10]LEE SS,PARK SH.Radiologic evaluation of nonalcoholic fatty liver disease[J].World J Gastroenterol,2014,20(23):7392-7402.

[11]ANGULO P,HUI JM,MARCHESINI G,et al.The NAFLD fibrosis score:a noninvasive tsystem that identifies liver fibrosis in patients with NAFLD[J].Hepatology,2007,45(4):846-854.

[12]WANG Y,LIANG J,LI HY,et al.Relationship of nonalcoholic fatty liver disease fibrosis score with metabolic syndrome and its components[J].Chin J endocrirol metab,2013,29(5):406-409.(in Chinese)王玉,梁军,李洪艳,等.非酒精性脂肪肝纤维化评分与代谢综合征及其各组分的相关性研究[J].中华内分泌代谢杂志,2013,29(5):406-409.

[13]MUSSO G,GAMBINO R,CASSADER M,et al.Meta-analysis:natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity[J].Ann Med,2011,43(8):617-649.

[14]ROMBOMS K,MARRA F.Molecular mechanisms of hepatic fibrosis in Non-alcoholic steatohepatitis[J].Dig Dis,2010,28(1):229-235.

[15]WEI YC,ZHU R,XIA LL,et al.Evaluation of different indices of insulin resistance in overweight and obese population[J].Shandong Med J,2015,55(46):14-16.(in Chinese)尉耘翠,祝茸,夏丽莉,等.超重及肥胖人群中不同胰岛素抵抗计算指数准确性评价[J].山东医药,2015,55(46):14-16.

[16]LIU ZY,LYU JX.Efficacy of Qianggan capsules in treatment of nonalcoholic fatty liver disease[J].Mod J Integr Tradit Chin West Med,2014,23(6):600-601.(in Chinese)刘子永,吕俊旭.强肝胶囊治疗非酒精性脂肪肝疗效观察[J].现代中西医结合杂志,2014,23(6):600-601.

[17]GU S,HUANG MX.Clinical observation of Qianggan capsule in the treatment of non alcoholic of non-alcoholic fatty liver fibrosis[J].Chin J Hepatol,2011,19(10):791-792.(in Chinese)古赛,黄秒兴.强肝胶囊治疗非酒精性脂肪性肝纤维化的疗效[J].中华肝脏病杂志,2011,19(10):791-792.

[18]HAO LH.Effects of Qianggan capsules on clinical symptoms and liver function in patients with nonalcoholic fatty liver disease[J].J Clin Med Pract,2015,19(1):126-127.(in Chinese)郝丽红.强肝胶囊对非酒精性脂肪肝患者临床症状改善情况及肝功能的影响[J].实用临床医药杂志,2015,19(1):126-127.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(16)

1.	巴明玉，潘研，王娴，陈亚琳，燕树勋. 强肝胶囊对非酒精性脂肪肝肥胖患者糖脂代谢水平及肝功能的影响. 中医学报. 2024(02): 416-420 .
2.	范文，郑垂仰，周旋，孔怡琳，潘丰满，杨钦河，张玉佩. 6种中成药治疗非酒精性脂肪性肝病有效性和安全性的网状Meta分析. 中药新药与临床药理. 2023(11): 1612-1622 .
3.	崔姗姗，刘英，江霞. 非酒精性脂肪性肝病与胰岛素抵抗的研究进展. 医学信息. 2022(10): 66-69 .
4.	舒祥兵，操颖，顾晔，杨志新，季光，张莉. 强肝胶囊促进肝糖原合成降低大鼠高血糖的机制研究. 上海中医药大学学报. 2021(03): 45-51 .
5.	贾英杰，张晓博，张新元，杨红霞，郭争荣. 强肝胶囊对猪血清诱导大鼠肝纤维化的治疗作用. 河北医药. 2021(20): 3104-3107 .
6.	朱丹，孙婷婷，陈兰羽，谢铮. 脂肪性肝病中医药认识. 辽宁中医药大学学报. 2020(05): 70-73 .
7.	崔翔，刘玲兰，华鹏，郭薇，薛敬东. 从脾论治非酒精性脂肪性肝病的体会与研究概况. 中医临床研究. 2020(14): 136-138 .
8.	郭明升，刘娟，郭英杰，籍芳华，郝艳爽. 阿托伐他汀联用脂康颗粒或强肝胶囊用于脑梗死二级预防效果比较. 现代中西医结合杂志. 2020(22): 2400-2404+2446 .
9.	王秀琴. 强肝胶囊联合甘草酸二铵肠溶胶囊治疗非酒精性脂肪肝的效果. 河南医学研究. 2019(06): 1089-1091 .
10.	黄静，陈湘清，郭东升，吴奋. 同步抗感染治疗对合并幽门螺杆菌感染非酒精性脂肪肝病患者治疗结局的影响研究. 重庆医学. 2018(01): 97-100 .
11.	陈少颖，易新宇，周小博，张荣臻. 中医药治疗非酒精性脂肪肝的研究进展. 大众科技. 2018(06): 68-70 .
12.	周桃梅，杨上文，汪剑波. 强肝胶囊联合二甲双胍治疗非酒精性脂肪肝的疗效及其对Nod样受体-3炎症小体的影响. 中国医院统计. 2018(03): 206-208 .
13.	柳琳琳，毛德文，吕建林，黄瑞. 强肝胶囊对非酒精性脂肪性肝病患者疗效及安全性的Meta分析. 中成药. 2018(08): 1715-1720 .
14.	李滨，张佳圆，王凤永，李春晖，齐丽韫，王玉华，赵培利. 胆宁片治疗非酒精性脂肪肝临床效果及对血脂、肝功能和肝纤维化的影响. 解放军医药杂志. 2018(10): 93-96 .
15.	朱紫馨，祝丽丽，程明亮. 同步抗感染治疗非酒精性脂肪肝合并幽门螺杆菌感染的效果观察. 临床合理用药杂志. 2018(31): 58-59 .
16.	李军祥，王允亮，郭一，谢添弘. 中医药治疗非酒精性脂肪性肝病专题笔谈. 中国中西医结合消化杂志. 2017(11): 801-804 .

Other cited types(13)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2565) PDF downloads(436)

Effect of Qianggan capsules on insulin resistance index and liver fibrosis score in patients with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2016.10.027